Podcasts about opportunistic infections

Host: Charles Flexner, MD Daily oral therapy can have low adherence, which is why the field of long-acting formulations is rapidly advancing. Tune in to hear Dr. Charles Flexner discuss how long-acting regimens can address this problem of adherence and help patients living with HIV, tuberculosis, malaria, and other infectious diseases. Dr. Flexner is a Professor of Medicine of Pharmacology, Molecular Sciences, and International Health at Johns Hopkins University, and he also presented a session on this exact topic at the 2024 Conference on Retroviruses and Opportunistic Infections.

Host: Charles Flexner, MD Daily oral therapy can have low adherence, which is why the field of long-acting formulations is rapidly advancing. Tune in to hear Dr. Charles Flexner discuss how long-acting regimens can address this problem of adherence and help patients living with HIV, tuberculosis, malaria, and other infectious diseases. Dr. Flexner is a Professor of Medicine of Pharmacology, Molecular Sciences, and International Health at Johns Hopkins University, and he also presented a session on this exact topic at the 2024 Conference on Retroviruses and Opportunistic Infections.

This week, Marianna sits down with John Faragon for the second part of our 2-part series talking all about CROI 2024, the Conference on Retroviruses and Opportunistic Infections. Learn about some of the studies that were presented, new drugs and strategies for tackling HIV, and more.--Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=LID6457)-- Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. Check out our free online courses: www.necaaetc.org/rise-coursesDownload our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

This week, Marianna sits down with John Faragon to talk all about CROI 2024, the Conference on Retroviruses and Opportunistic Infections. Find out everything that went down from DoxyPEP data to injectable treatments and more. --Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=WGM6434)-- Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. Check out our free online courses: www.necaaetc.org/rise-coursesDownload our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of "what you need to know" videos from data presented at CROI 2024. Launch Date: March 12, 2024Release Date: March 12, 2024Expiration Date: February 28, 2025 ACTIVITY DESCRIPTION In this podcast, Dr. Hodder will present highlights from the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. FACULTY BIODr. Sally Hodder is a Professor of Medicine at West Virginia University and the Associate Vice President of Clinical and Translational Research at West Virginia University Health.   This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-the-2024-conference-on-retroviruses-and-opportunistic-infections-1

These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of "what you need to know" videos from data presented at CROI 2024. Launch Date: March 12, 2024Release Date: March 12, 2024Expiration Date: February 28, 2025 ACTIVITY DESCRIPTION In this podcast, Dr. Hodder will present highlights from the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. FACULTY BIODr. Sally Hodder is a Professor of Medicine at West Virginia University and the Associate Vice President of Clinical and Translational Research at West Virginia University Health.   This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-the-2024-conference-on-retroviruses-and-opportunistic-infections-1

These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of "what you need to know" videos from data presented at CROI 2024. Launch Date: March 12, 2024Release Date: March 12, 2024Expiration Date: February 28, 2025 ACTIVITY DESCRIPTION In this podcast, Dr. Hodder will present highlights from the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. FACULTY BIODr. Sally Hodder is a Professor of Medicine at West Virginia University and the Associate Vice President of Clinical and Translational Research at West Virginia University Health.   This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-the-2024-conference-on-retroviruses-and-opportunistic-infections-1

These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of "what you need to know" videos from data presented at CROI 2024. Launch Date: March 12, 2024Release Date: March 12, 2024Expiration Date: February 28, 2025 ACTIVITY DESCRIPTION In this podcast, Dr. Hodder will present highlights from the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. FACULTY BIODr. Sally Hodder is a Professor of Medicine at West Virginia University and the Associate Vice President of Clinical and Translational Research at West Virginia University Health.   This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-the-2024-conference-on-retroviruses-and-opportunistic-infections-1

In this episode, Raymund Razonable, MD, discusses cytomegalovirus (CMV) management strategies beyond primary prophylaxis in solid organ transplantation recipients including:CMV treatment goals CMV treatment and monitoring recommendationsRole of secondary prophylaxisUse of CMV cell–mediated immunity (CMI) monitoring for CMV relapse riskUse of CMV CMI for secondary prophylaxis Proposed use of CMV CMI monitoring for secondary prophylaxisIncidence and outcomes with antiviral resistance Risk factors for CMV resistanceWhen to suspect antiviral resistance Testing for antiviral resistance using genotypic assaysOutcomes in patients with ganciclovir-resistant vs ganciclovir-susceptible virusTreatment recommendations for resistant/refractory CMVEfficacy and safety of maribavir vs investigator-assigned therapy for resistant/refractory CMV infections from the phase III SOLTICE studyTreatment algorithm for resistant/refractory CMV Adjunctive, investigational, and off-label treatment options for resistant/refractory CMV Faculty:Raymund Razonable, MDProfessor of MedicineProgram Director, Infectious Diseases FellowshipVice Chair, Division of Infectious DiseasesMayo ClinicRochester, Minnesota Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/47lNK2K

When I found myself struggling to communicate a patient's HIV status during a rapid response, it was a wake-up call that I needed to expand my knowledge. This podcast episodes delves deeper into HIV/AIDS than nursing school did, covering common hospital presentations, labs, medications, and opportunistic infections. By enhancing my own understanding, I hope to equip others to improve care for patients living with HIV/AIDS.Check out Nicole Kupchik's exam reviews and practice questions at nicolekupchikconsulting.com. Use the promo code UPMYGAME20 to get 20% off all products.Do you need help with your resume, interviewing, or need career coaching? Check out Sarah at New Thing Nurse:Get 15% off of her resume and cover letter templates using the promo code UPMYGAMENursing students and new grad career services Experienced RN career servicesNP career servicesUp My Nursing Game is partnering with VCU Health Continuing Education to offer FREE continuing education credits for registered nurses. Click here to obtain nursing credit.See the show notes at upmynursinggame.com.The key moments in this episode are:00:02:33 - Overview of HIV/AIDS00:05:00 - Treatment of HIV00:09:15 - Opportunistic Infections 00:13:57 - Patient Education 

Drs Michael S. Saag and David H. Spach discuss HIV and the nuances of primary care treatment, with a special focus on vaccines, including COVID, hepatitis, varicella zoster virus, and mpox. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986508). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources HIV Infection and AIDS https://emedicine.medscape.com/article/211316-overview HIV and Immunizations https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-immunizations HRSA Ryan White HIV/AIDS Program https://ryanwhite.hrsa.gov/about/parts-and-initiatives Pneumococcal Vaccination https://www.cdc.gov/pneumococcal/vaccination.html Incidence and Risk Factors for Invasive Pneumococcal Disease in HIV-Positive Individuals in the Era of Highly Active Antiretroviral Therapy https://pubmed.ncbi.nlm.nih.gov/30999829/ Pneumococcal 7-Valent Conjugate Vaccine https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pneumococcal-7-valent-conjugate-vaccine Immunizations for Preventable Diseases in Adults and Adolescents Living With HIV https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/immunizations Drug Database: Hepatitis B Vaccine https://clinicalinfo.hiv.gov/en/drugs/hepatitis-b-vaccine/patient Interpretation of Hepatitis B Laboratory Results https://www.cdc.gov/hepatitis/statistics/surveillanceguidance/docs/viral-hepatitis-surveillance-table-3-1_508.pdf Screening and Testing for Hepatitis B Virus infection: CDC Recommendations — United States, 2023 https://www.cdc.gov/mmwr/volumes/72/rr/rr7201a1.htm?s_cid=rr7201a1_w Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Hepatitis B Virus Infection https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/hepatitis-b-0?view=full Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/what-start-initial-combination-regimens Cabotegravir/Rilpivirine (Rx) Cabenuva (cabotegravir/rilpivirine) dosing, indications, interactions, adverse effects, and more https://reference.medscape.com/drug/cabenuva-cabotegravir-rilpivirine-4000156 Dolutegravir/Lamivudine as a First-Line Regimen in a Test-and-Treat Setting for Newly Diagnosed People Living With HIV https://pubmed.ncbi.nlm.nih.gov/34115650/ Systematic Review and Meta-analysis of Immune Response of Double Dose of Hepatitis B Vaccination in HIV-Infected Patients https://pubmed.ncbi.nlm.nih.gov/32334887/ Heplisav-B® (HepB-CpG) Vaccine https://www.cdc.gov/vaccines/schedules/vacc-updates/heplisav-b.html PreHevbrio: A New 3-Antigen Hepatitis B Vaccine for Adults https://pubmed.ncbi.nlm.nih.gov/35906803/ Hepatitis A Vaccine Inactivated (Rx) https://reference.medscape.com/drug/vaqta-havrix-hepatitis-a-vaccine-inactivated-343150 Hepatitis A/B Vaccine (Rx) https://reference.medscape.com/drug/twinrix-hepatitis-a-b-vaccine-343152 Zoster Vaccine Recombinant (Rx) https://reference.medscape.com/drug/shingrix-zoster-vaccine-recombinant-1000163 Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 https://www.cdc.gov/mmwr/volumes/71/wr/mm7103a2.htm#:~:text=On%20October%2020%2C%202021%2C%20ACIP,for%20use%20in%20immunocompromised%20persons. Live Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine) https://www.cdc.gov/flu/prevent/nasalspray.htm MMR Vaccine https://www.ncbi.nlm.nih.gov/books/NBK554450/

Confused by all the possible opportunistic infections that patients with HIV may be vulnerable to? Take a listen! Written by: Dr. Valerie Kim (Internal Medicine Resident). Reviewed by: Dr. Nisha Andany (Infectious Disease Specialist) and Dr. Isaac Bogoch (Infectious Disease Specialist and Internal Medicine Physician). Infographic: Also by Dr. Valerie Kim.  Support the show

This week, we're sitting down with John Faragon the final installment of our 3-part series covering the Conference on Retroviruses and Opportunistic Infections - or CROI – which took place in February 2023. Learn about some of the key studies discussed, investigational medications for HIV, and more. --Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=LXG4838)

This week, we're sitting down with John Faragon for part two of our series covering the Conference on Retroviruses and Opportunistic Infections - or CROI – which took place in February 2023. Learn about the latest in regards to HIV prevention data, treatment, and more.  --Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=CQX4820)

This week, Marianna sits down with John Faragon to talk all things CROI 2023. CROI is the Conference on Retroviruses and Opportunistic Infections, which took place in February 2023. Find out what happened, what you may have missed, and why it matters for your as an HIV care provider. --Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=XJM4792)

Conference clinical cochair Diane Havlir, MD, a professor of medicine at the University of California, San Francisco, sits down with JAMA Deputy Editor Preeti Malani, MD, MSJ, about research highlights presented at the 30th annual CROI, held in Seattle. The infectious disease experts discuss postexposure prophylaxis for sexually transmitted infections, a new protease inhibitor for COVID-19, goals for preventing HIV transmission, and more. Related Content: Highlights From CROI, the Conference on Retroviruses and Opportunistic Infections—Postexposure Prophylaxis for Sexually Transmitted Infections, a New Protease Inhibitor for COVID-19, Goals for Preventing HIV Transmission, and More

In this podcast, Jonathan Appelbaum, MD, FACP, AAHIVS, summarizes the many medical challenges faced by aging people with HIV, including:Underrepresentation of older patients in medical researchConsequences of early experiences in the epidemic such as late HIV diagnosis and low CD4+ cell count nadir, incomplete or short-lived virologic suppression with early regimens, and toxicity associated with early antiretroviral agentsAdded challenges of multimorbidity and psychosocial challenges, especially mental health issues, loneliness, and social isolationThe need to provide care for the aging HIV population using a holistic approach Gaps in the current healthcare system in providing optimal care for aging people with HIVFaculty:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier Jr, MD, Education DirectorProfessor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineTallahassee, FloridaLink to full program: https://bit.ly/3KkF4iZ

On this episode, we discuss the opportunistic infections that affect patients with HIV and low CD4 counts. We review coccidioidomycosis, pneumocystis, histoplasmosis, toxoplasma, cryptococcal meningitis, and mycobacterium avium complex (MAC).  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We continue to partner with freeCE to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. To earn credit for this episode, visit the link provided in the show description to earn CE for listening to this podcast episode: FreeCE Podcast CE Link For existing freeCE members, this CE option is included in your membership benefits at no additional cost! Members can simply follow the link above to take the post-test and evaluation for this activity. Use the password RISK (all caps) to unlock the post-test for this episode. But if you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. CorConsult Rx listeners can save 15% off the purchase of an unlimited membership by entering the discount code “PODCAST2022” at checkout, or by clicking the following link in the description https://hubs.ly/Q012N0H60 Thanks for listening! We want to give a big thanks to our main sponsor Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:  www.patreon.com/corconsultrx If you have any questions for Cole or me, reach out to us on any of the following: Text - 415-943-6116 Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com Instagram and other social media platforms - @corconsultrx This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.  

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss important considerations for ART with opportunistic infections, including: When to start ART with pneumocystis pneumonia including discussion of the ACTG 5164 study of immediate vs delayed ART with opportunistic infectionsEACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of most opportunistic infectionsConsiderations for the administration of ART to patients who are unable to swallow or critically ill and intubatedTreatment of Kaposi sarcoma and considerations for starting ART to avoid drug–drug interactions with Kaposi sarcoma treatmentConsiderations for starting ART with cytomegalovirus and the risk for IRIS from cytomegalovirusDiscussion of treatment of cytomegalovirus and overlapping toxicities between its treatment and ARTWhen to start ART with cryptococcal meningitis and the data to support delayed treatment initiation with this particular opportunistic infectionEACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of cryptococcal meningitis specificallyTreatment of cryptococcal meningitis and managing drug–drug interactions between ART and antifungal therapyPresenters:Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics University HospitalUniversity of Modena and Reggio EmiliaReggio Emilia, Italy William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, Pennsylvania Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3uktrm1Link to full program:https://bit.ly/3q2DlGd

Can an oral COVID-19 treatment prevent hospitalization and death in unvaccinated patients? Find out about this and more in today's PV Roundup podcast.

An American research team reported that it has possibly cured HIV in a woman for the first time, A group of scientists presented some of the details of the new case on Tuesday at the Conference on Retroviruses and Opportunistic Infections in Denver, Colorado.She is believed to be the third person ever to be cured of the disease.According to scientists, she was cured using a new transplant method involving umbilical cord blood that opens up the possibility of curing more people of diverse racial backgounds than was previously possible.Cord blood is more widely available than the adult stem cells typically used in bone marrow transplants, and does not need to be matched as closely to the recipient, the Times reported.“The fact that she's mixed race, and that she's a woman, that is really important scientifically and really important in terms of the community impact,” said Dr. Steven Deeks, an AIDS expert at the University of California, San Francisco who was not involved in the work.

A friend from twitter approached me several months ago with this painful personal story about a close, lifelong friend whose life takes a very dark and destructive turn after becoming redpilled in 2017.CONTENT WARNING:This episode recounts trauma and traumatic events -- including death by suicide -- and is not presented for prurient interest.  What I hope you can take away from this is two people working through to a slightly better understanding of what certain types of conflict and trauma have in common and how we deal with it.  Finally: this story involves QAnon, but what you will quickly learn is that my take here is that Q/MAGA/whatever is incidental to what ultimately happens in this particular instance.   There are much more qualified and experienced people covering this beat and I reference them often.  Listeners curious about these tops should reference the QAA podcast, researchers like Mike Rothschild, Mark Andre Argentino,  and journalists and researchers like Will Sommer and Jared Holt.Support the show (HTTPS://www.Patreon.com/Nicepilled )

Hear insights from 3 faculty experts as they present emerging data and guidelines and engage in discussion on patient-centered ART selection for people with HIV.Topics include assessing treatment options; individualizing ART for women of childbearing potential and during pregnancy, patients with OIs, and during the COVID-19 pandemic; and new data on investigational ART strategies. Learn how to:Apply the results of recent clinical studies and evolving treatment guidelines on the timing and choice of first-line ART and switch strategies and managing treatment-experienced patients with HIVIntegrate individual patient factors such as drug–drug interactions, comorbidities, pregnancy status, adherence, and dosing preferences when selecting optimal ARTAppropriately counsel patients regarding the anticipated clinical role of new and investigational ART regimens in individualized carePresenters:Chloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomJean-Michel Molina, MD, PhDHead of the Department ofInfectious DiseasesSaint-Louis Hospital, Assistance-Publique Hôpitaux de ParisProfessor of Infectious DiseasesUniversity of ParisParis, FranceCristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics University HospitalUniversity of Modena and Reggio EmiliaReggio Emilia, ItalyFollow along with the slides at: https://bit.ly/329c8ZPSee the entire program at:https://bit.ly/3FkRofM

Join us today as we sit down with Dr. Chevaliar, Dr. Gutman, Dr. Itty and Dr. Kaur to talking about Opportunistic Infections.

This week, we sit down with John Faragon to talk all about the latest update from CROI, the Conference on Retroviruses and Opportunistic Infections. Learn all about the latest in COVID treatment, COVID disparities in care, new HIV medications, and PrEP. (Help us track how many listeners our episode gets by filling out this brief form!)

In this podcast, Vinay Pathak, PhD, discusses the implications of his research presented in the session “Live-Cell Imaging of HIV-1 Nuclear Import, Uncoating, and Proviruses” at the Conference on Retroviruses and Opportunistic Infections 2021. For more, visit www.consultant360.com.

In this podcast, Jyoti Mathad, MD, MS, talks about her session Pregnancy, HIV, and Tuberculosis: Current Practices and Research Opportunities at the Conference on Retroviruses and Opportunistic Infections 2021, including progress on TB prevention therapies in pregnancy, and the large gaps that exist in the studies. More on Consultant360.com

In this podcast, Jonathan Karn, PhD, talks about his session Novel Findings of Neuronal Modulation of HIV Expression in Microglia at the Conference on Retroviruses and Opportunistic Infections 2021, including some controversies among researchers about HIV infection of the brain.

Dolores de cabeza, hinchazón después de comer, alergias, dermatitis atópica, esos kilos de más de los que es imposible deshacerse... Quizás te suenen algunos de estos problemas, pero ¿sabías que todos ellos pueden estar relacionados con un desequilibrio de la microbiota? Los descubrimientos sobre la microbiota constituyen una de las mayores revoluciones de la historia de la ciencia y la medicina. Los microorganismos están en todas partes: desde el ojo de un huracán hasta la pantalla del móvil. Son los responsables de cómo nos sienta la comida, cómo luce nuestra piel e incluso cómo funciona nuestra memoria. Para comprender mejor el papel vital que estos microorganismos desempeñan en nuestra salud y nuestras vidas, el programa de hoy cuenta con una verdadera experta en el tema, Sari Arponen, Doctora en Medicina por la Universidad Complutense de Madrid (número de colegiado 282856021), socia de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, de GESIDA, y de la Sociedad Española de Medicina Interna, además de miembro de la European Network of Young HIV Experts. Por otro lado, ha recibido el Premio al Joven Investigador concedido para la asistencia al CROI 2008 (15th Conference on Retroviruses and Opportunistic Infections), y fue elegida “Mejor Médico del Año 2010” (premio compartido) en el Hospital Infanta Leonor, Madrid. Tras casi veinte años de experiencia clínica en la sanidad pública española, en la actualidad se dedica a la formación y divulgación en el ámbito de la microbiota y la medicina del estilo de vida. También pasa consulta aplicando un enfoque basado en la medicina evolutiva y sus conocimientos sobre la microbiota. Además, es cofundadora de «Slow Medicine Revolution», una plataforma de divulgación sobre salud y estilo de vida con perspectiva evolutiva. La doctora acaba de publicar un libro donde comparte todos sus hallazgos en este campo con un lenguaje sencillo, lo podéis encontrar aquí: https://amzn.to/37PLt3G Podéis conseguir el e-book de alimentación prebiótica y antiinflamatoria GRATIS aquí: https://drasariarponen.com/blog/alimentacion-prebiotica-y-antiinflamatoria/ Tenéis infografías muy útiles aquí: https://www.gutmicrobiotaforhealth.com/es/recursos/recursos-infografias/ Podéis seguir a la doctora Arponen aquí: https://drasariarponen.com https://www.facebook.com/drasariarponen/ https://www.instagram.com/drasariarponen/

This episode covers opportunistic infections and diseases in patients with AIDS!

HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.   These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.   In this episode of HOPA Now, Dr. Katie Gatwood provides an overview of the goals of and indications for hematopoietic stem cell transplantation, which is often the only curative treatment option for several malignant and non-malignant diseases. She covers the goals and considerations of hematopoietic stem cell transplantation, common indications for allogeneic transplants, the three conditioning chemotherapy regimens that are administered prior to stem cell infusion, and key supportive considerations for hematopoietic stem cell transplant recipients.   In this episode you will learn:   Hematopoietic stem cell transplantation and opportunistic infections The goals of hematopoietic stem cell transplantation include eradicating disease, restoring normal hematopoiesis, and to induce immunologic activity to prevent disease relapse. Stem cell transplantation considerations and donor options for transplants Common indications for allogeneic transplants and sources of hematopoietic stem cells Three conditioning chemotherapy regimens that are administered prior to stem cell infusion Leading causes of transplant-related morbidity and mortality Understanding infection as one of the leading causes of transplant-related mortality Key supportive considerations for hematopoietic stem cell transplant recipients   Mentioned in This Episode: HOPA   Tweetables: “Stem cell transplantation is used only to administer high dose chemotherapy.” — Dr. Katie Gatwood   “Peripheral blood is most commonly utilized due to ease of collection and low graft failure rate and faster engraftment time.” — Dr. Katie Gatwood   “Stem cell transplant infection is one of the leading causes of transplant-related mortality.” — Dr. Katie Gatwood  

HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.   These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.   In this episode of HOPA Now, Dr. Katie Gatwood offers a quick and convenient resource regarding hematopoietic stem cell transplantation and opportunistic infections to assist you in caring for your transplant patients. She highlights the indications for effective transplant, general indications, and strategies, and leading causes of transplant-related morbidity and infections. She also offers management and prevention tactics to help best overcome major infection concerns.   In this episode you will learn:   An overview of hematopoietic stem cell transplantation and opportunistic infections Indications for effective transplant, the curative treatment for over 70 different malignant and non-malignant conditions Stem cell mobilization strategies and general indications Intensity levels and other criteria of various transplant conditioning regimens, including the high-risk VOD Standard practices for prevention of GVHD and allogeneic transplantation Leading causes of transplant-related morbidity and mortality GVHD and effective treatment options Risks and management of CMV, including preemptive therapy Management of and major concerns regarding EBV reactivation The reason that reimmunization of vaccine-preventable diseases is required following transplantation   Mentioned in This Episode: HOPA   Quotes:   “Acute leukemias are the most common indications for allogeneic transplant.” — Katie Gatwood   “For patients at high risk for mobilization failure … combination strategies are generally preferred.” — Katie Gatwood   “Despite prophylaxis, 30–80% of patients will develop GVHD.” — Katie Gatwood   “Following transplantation, patients are at a major risk for CMV reactivation and disease, which is associated with significant morbidity.” — Katie Gatwood  

Dr. Anupama Raghuram discusses OIs in HIV by first reviewing pathogenesis, clinical manifestations, diagnosis, and select opportunistic infections in HIV positive patients. She then discusses challenges in diagnosis and treatment options for select OIs in HIV positive patients.   Some items in this lecture may have come from the lecturer’s personal academic files or have been cited in-line or at the end of the lecture. For more information, see our citation page.   Disclaimers ©2016 LouisvilleLectures.org

AIDS Lecture

Click here for audio of lecture.

On episode #73 of the podcast This Week in Virology, Vincent, Dickson, and Rich discuss multipotent progenitor bone marrow cells as a reservoir of HIV-1, integration of HHV-6 into telomeres, and dispersal of West Nile virus across the US by mosquitoes. Host links Vincent Racaniello, Dickson Despommier, and Rich Condit Links for this episode: HIV-1 infects multipotent progenitor cells HHV-6 genome integrates into telomeres A role for mosquito-mediated dispersal of West Nile virus across the US Using tobacco mosaic virus to produce synthetic photovoltaic cells (thanks Nissin!) Animation of HIV replication cycle (thanks Ilya!) Can computer viruses evolve? (thanks Norman!) Mumps outbreak in Israel (one and two) (thanks Ariel!) Bocavirus infections in children (thanks Tyler!) Weekly science picks: Dickson Whole-Genome Sequencing in a Patient with Charcot–Marie–Tooth Neuropathy (NEJM and NY Times) Rich Invisible Frontiers: The Race to Synthesize a Human Gene by Stephen Hall Vincent Conference on Retroviruses and Opportunistic Infections - videocasts

LSHTM Audio News Review - September 12th, 2007 A supplement to LSHTM Audio News reviewing this year's important medical developments. Road-Side Tranexamic Acid Therapy to Reduce Mortality and Blood Transfusions after Trauma? The multi-national CRASH trial investigates whether the antifibrinolytic agent, tranexamic acid normally used to reduce bleeding during surgery can also be used as a first-aid to cut mortality and the need of blood transfusion immediately after trauma. Jaime Miranda, based in Lima, Peru, described to Peter Goodwin how the trial could benefit the developing world in particular. Growth Hormones: Slimming Aid for Patients Receiving HAART? Daily administration of the growth hormone releasing factor, TH9507, to patients with HIV receiving Highly Active Anti Retroviral Therapy (HAART) can help to reduce cardiovascular risk factors, according to Steven Grinspoon, who presented a paper on this at the Conference on Retroviruses and Opportunistic Infections, held in Los Angeles. He talked about his study with Dan Keller, who discussed the paper with Judith Currier. Raltegravir Doubled Antiviral Response Rates in Treatment-Experienced HIV-Infected Patients The integrase inhibitor raltegravir (one of a new class of anti-retroviral agents) blocks enzymes that allow HIV's nuclei acid to integrate into the DNA of host cells. The BENCHMRK study found that patients with HIV who are resistant to at least one drug in each of the nucleoside, non-nucleoside, and protease inhibitor classes, have doubled antiviral response rates and increased CD4 cells when taking raltegravir. Roy Steigbigel explained the study to Dan Keller in Los Angeles. John Mellors commented on the findings. Non-Perfect HIV Vaccine: Major Benefits There is good hope that a useful vaccine for HIV will be developed soon. Anthony Fauci wrote in the New England Journal Medicine (and explained to Derek Thorne for Audio News) that although a perfect vaccine may not emerge, a non-perfect vaccine will nevertheless be of great use, by slowing disease progression and also reducing the spread of disease.

How do you make heads or tails of an HIV medical conference with 1,000 presentations? Surely the 14th Conference on Retroviruses and Opportunistic Infections -- better known as CROI -- is a gold mine of critical studies on every facet of HIV, from prevention to treatment to quality of life. We've covered this conference extensively on our site, but for people with nonmedical backgrounds, this coverage may be difficult to put into context. That's why, for our March edition of "This Month in HIV," we've interviewed two experts who can break down the conference highlights for people who aren't experts. Physician and researcher Joel Gallant, and HIV-positive activist Nelson Vergel, tell us about the breaking research that really mattered at CROI this year.

Audio Journal of Global Health Issues 6 Months Exclusive Breast Feeding for Mothers with HIV Lowers Transmission Rates REFERENCE: Abstract 13, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007 HOOSEN COOVADIA, University of KwaZulu-Natal, Durban In the developing world breastfeeding is the recommended infant feeding method, even for women infected with HIV. While early cessation of breastfeeding reduces HIV transmission to the baby, studies have shown that it increases morbidity and mortality in the infants. Exclusive breastfeeding for the first six months of life appears to reduce HIV transmission, as opposed to “mixed” breastfeeding with supplementation with formula or solid foods. Dan Keller spoke with Hoosen Coovadia, who delivered a plenary talk on the subject at the14th Conference on Retroviruses and Opportunistic Infections in Los Angeles.

Audio Journal of Global Health Issues Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety REFERENCE: Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007 HOWARD MAYER, Pfizer Global Research, New London CT MARK WAINBERG, McGill University, Montreal In a population of treatment-experienced HIV-infected subjects, maraviroc plus optimised background antiretroviral therapy provided significantly superior virologic control and increases in CD4 cell counts compared with placebo plus optimized background therapy. There were no clinically relevant differences in the safety profiles between the maraviroc and the placebo treatment groups. These drugs do not attack the virus itself but rather block host cells’ CCR5 cell surface cytokine receptors that HIV interacts with to gain entry into the cell.

Audio Journal of Global Health Issues Integrase Inhibitor Raltegravir Doubles Antiviral Response Rate in Treatment Experienced HIV-Infected Patients Compared to Optimised Background Therapy Alone REFERENCE: Abstract 105aLB, 105bLB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007 ROY STEIGBIGEL, State University of New York at Stony Brook JOHN W. MELLORS, University of Pittsburgh Raltegravir doubled the antiviral response rate and the increase in CD4 cells among treatment-experienced HIV-infected patients who were resistant to at least one drug in each of the nucleoside, non-nucleoside, and protease inhibitor classes. Two placebo controlled trials (BENCHMRK-1 and BENCHMRK-2) randomized a total of almost 700 subjects to either raltegravir 400 mg twice daily or to placebo, each on a background of optimized antiviral background therapy. Raltegravir is an integrase inhibitor and acts to block the enzyme that allows HIV’s nuclei acid to integrate into the DNA of host cells.

Audio Journal of Global Health Issues Entecavir Shows Activity Against HIV But Also Selects for an Antiretroviral Drug Resistance Mutation REFERENCE: Abstract: 136LB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-29, 2007 CHLOE THIO, Johns Hopkins University School of Medicine Entecavir, used to treat hepatitis B virus infections, can lower levels of HIV in co-infected patients but also selects for a mutation that makes HIV resistant to entecavir as well as the antiretroviral drugs lamivudine and emtracitabine. These findings, derived from three case reports and associated laboratory studies, have important implications for the treatment of HBV in HIV-infected patients. Current guidelines, issued in October 2006 and which recommend entecavir as a first-line treatment of HBV in co-infected individuals who do not require anti-HIV therapy, need to be reconsidered. Chloe Thio discussed her study results and their implications with Dan Keller at the 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles.

Audio Journal of Global Health Issues Growth Hormone Releasing Factor Analog: Slimming Aid for Patients Receiving HAART? REFERENCE: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-29, 2007 STEVEN GRINSPOON, Massachusetts General Hospital, Boston COMMENT: JUDITH CURRIER, University of California, Los Angeles Daily administration of an analog of growth hormone releasing factor to HIV patients receiving highly active antiretroviral therapy significantly decreased visceral fat and improved their lipid profiles. This development-stage drug, TH9507, was well tolerated and may help patients reduce central fat accumulation and abnormal lipid profiles, both of which are know cardiovascular risk factors. In addition, decreases in central fat may have a positive effect on patients' self-image. Steven Grinspoon gave Dan Keller details during the 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles.

Hello this is Dr. Eric Daar calling from Denver, Colorado from the 13th Conference on Retroviruses and Opportunistic Infections or CROI 2006. Last day of conference (February 8th). It has been an extremely exciting day with some very important presentations in the area of complications of antiretroviral therapy and new treatments. The first presentation was from the CDC describing the experience in Uganda in over a thousand individuals started on antiretroviral therapy for the first time. There has been a major rollout of therapy in the developing world and this one with another report, were one of the largest to describe the tolerability of such therapy. This looked at over 1,000 individuals from 2003-2004 started on standard first line regimen in the developing world.

Hello this is Dr. Eric Daar calling from Denver, Colorado from the 13th Conference on Retroviruses and Opportunistic Infections or CROI 2006. Update on meeting on second full day (February 7th). There were actually a series of world presentations all dealing with the related topic of treatment interruptions. Recently, a great deal of attention came to this area with the announcement of the data safety monitoring board closing one of these very important studies that was presented as a late breaker. The study was called SMART. It was a study through the CPCRA and the strategy was to determine whether you could take individuals with greater than 350 T cells and randomly assign them to either continue on their current therapy or interrupt their treatment with the plan of them restarting therapy if their CD4 count should drop to less than 250.

Hello this is Dr. Eric Daar calling from Denver, Colorado from the 13th Conference on Retroviruses and Opportunistic Infections or CROI 2006. This meeting opened with a Plenary session and keynote lecture on Sunday, February 5th. The keynote was presented by Dr. James Kern on 25 years of the HIV pandemic, where he described his experience at the CDC in the first reported cases of AIDS in 1981 in Los Angeles. He emphasized the many advances in the following years as well as the obstacles overcome and the obstacles that are left to be overcome both with prevention, the development of vaccine, and the potential hope for eradication

Hello this is Dr. Eric Daar calling from Denver, Colorado from the 13th Conference on Retroviruses and Opportunistic Infections or CROI 2006. This has been traditionally now one of the main HIV research meetings of the year. There are 3800 researchers from around the world who have converged on Denver to present new information on both clinical and laboratory based research as well as behavioral research related to HIV and AIDS. Numerous important presentations from many investigators around the world including some important opening keynote presentations on the evening of February 5th